Literature DB >> 20035059

Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells.

Kou Kayamori1, Kei Sakamoto, Tomoki Nakashima, Hiroshi Takayanagi, Kei-Ichi Morita, Ken Omura, Su Tien Nguyen, Yoshio Miki, Tadahiro Iimura, Akiko Himeno, Takumi Akashi, Hisafumi Yamada-Okabe, Etsuro Ogata, Akira Yamaguchi.   

Abstract

We investigated the roles of interleukin-6 (IL-6) and parathyroid hormone-related peptide (PTHrP) in oral squamous cell carcinoma (OSCC)-induced osteoclast formation. Microarray analyses performed on 43 human OSCC specimens revealed that many of the specimens overexpressed PTHrP mRNA, but a few overexpressed IL-6 mRNA. Immunohistochemical analysis revealed that IL-6 was expressed not only in cancer cells but also in fibroblasts and osteoclasts at the tumor-bone interface. Many of the IL-6-positive cells coexpressed vimentin. Conditioned medium (CM) derived from the culture of oral cancer cell lines (BHY, Ca9-22, HSC3, and HO1-u-1) stimulated Rankl expression in stromal cells and osteoclast formation. Antibodies against both human PTHrP and mouse IL-6 receptor suppressed Rankl in ST2 cells and osteoclast formation induced by CM from BHY and Ca9-22, although the inhibitory effects of IL6 antibody were greater than those of PTHrP antibody. CM derived from all of the OSCC cell lines effectively induced IL-6 expression in stromal cells, and the induction was partially blocked by anti-PTHrP antibody. Xenografts of HSC3 cells onto the periosteal region of the parietal bone in athymic mice presented histology and expression profiles of RANKL and IL-6 similar to those observed in bone-invasive human OSCC specimens. These results indicate that OSCC provides a suitable microenvironment for osteoclast formation not only by producing IL-6 and PTHrP but also by stimulating stromal cells to synthesize IL-6.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035059      PMCID: PMC2808100          DOI: 10.2353/ajpath.2010.090299

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

Authors:  William G Gunn; Adam Conley; Lisa Deininger; Scott D Olson; Darwin J Prockop; Carl A Gregory
Journal:  Stem Cells       Date:  2005-11-17       Impact factor: 6.277

2.  Osteoclasts constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study.

Authors:  R J O'Keefe; L A Teot; D Singh; J E Puzas; R N Rosier; D G Hicks
Journal:  Lab Invest       Date:  1997-04       Impact factor: 5.662

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells.

Authors:  Carlos Guillén; Pilar Martínez; Arancha R de Gortázar; María Eugenia Martínez; Pedro Esbrit
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

5.  Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.

Authors:  Takeyuki Tada; Eijiro Jimi; Masato Okamoto; Satoru Ozeki; Koji Okabe
Journal:  Int J Cancer       Date:  2005-08-20       Impact factor: 7.396

6.  Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer.

Authors:  Ewa Jablonska; Leszek Piotrowski; Zyta Grabowska
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

7.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.

Authors:  B Arnulf; S Lecourt; J Soulier; B Ternaux; M-Noelle Lacassagne; A Crinquette; J Dessoly; A-K Sciaini; M Benbunan; C Chomienne; J-P Fermand; J-P Marolleau; J Larghero
Journal:  Leukemia       Date:  2006-11-09       Impact factor: 11.528

8.  Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma.

Authors:  Yasushi Fukaya; Hiroyuki Shimada; Ling-Chi Wang; Ebrahim Zandi; Yves A DeClerck
Journal:  J Biol Chem       Date:  2008-05-01       Impact factor: 5.157

9.  Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.

Authors:  J de la Mata; H L Uy; T A Guise; B Story; B F Boyce; G R Mundy; G D Roodman
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy.

Authors:  W J Burtis; T Wu; C Bunch; J J Wysolmerski; K L Insogna; E C Weir; A E Broadus; A F Stewart
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

View more
  24 in total

1.  Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells.

Authors:  Jacqueline A Gasche; Jürgen Hoffmann; C Richard Boland; Ajay Goel
Journal:  Int J Cancer       Date:  2011-01-07       Impact factor: 7.396

Review 2.  [Advances in molecular mechanisms of bone invasion by oral cancer].

Authors:  Wei Liu; Chun-Jie Li; Long-Jiang Li
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-04-01

3.  Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma.

Authors:  Chelsea K Martin; Wessel P Dirksen; Sherry T Shu; Jillian L Werbeck; Nanda K Thudi; Mamoru Yamaguchi; Tobie D Wolfe; Kristin N Heller; Thomas J Rosol
Journal:  Oral Oncol       Date:  2012-01-21       Impact factor: 5.337

4.  Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

Authors:  Lanxi Song; Matthew A Smith; Parul Doshi; Kate Sasser; William Fulp; Soner Altiok; Eric B Haura
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

5.  Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.

Authors:  Chelsea K Martin; Jillian L Werbeck; Nanda K Thudi; Lisa G Lanigan; Tobie D Wolfe; Ramiro E Toribio; Thomas J Rosol
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

6.  Bone-invasive oral squamous cell carcinoma in cats: pathology and expression of parathyroid hormone-related protein.

Authors:  C K Martin; S H Tannehill-Gregg; T D Wolfe; T J Rosol
Journal:  Vet Pathol       Date:  2010-10-12       Impact factor: 2.221

Review 7.  Muscle-bone and fat-bone interactions in regulating bone mass: do PTH and PTHrP play any role?

Authors:  Nabanita S Datta
Journal:  Endocrine       Date:  2014-05-07       Impact factor: 3.633

Review 8.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

9.  Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.

Authors:  Xiaoyi Zhang; Carlos Rossa Junior; Min Liu; Fei Li; Nisha J D'Silva; Keith L Kirkwood
Journal:  Oral Oncol       Date:  2012-09-16       Impact factor: 5.337

10.  Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.

Authors:  Lucas Novaes Teixeira; Larissa Moreira Spinola de Castro Raucci; Gabriela Caroline Alonso; Ricardo Della Coletta; Adalberto Luiz Rosa; Paulo Tambasco de Oliveira
Journal:  Tumour Biol       Date:  2016-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.